CLM
AKBA icon

ClearBridge LLC (Maryland)’s Akebia Therapeutics AKBA Stock Holding History

ClearBridge LLC (Maryland)’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-494,361
Closed -$113M – 94
2018
Q2 		$113M Buy
+494,361
New +$4.95M 1.89% 13

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

ClearBridge LLC (Maryland)'s AKBA Position: Q3 2018 in Review

ClearBridge LLC (Maryland) sold out of Akebia Therapeutics (AKBA) in Q3 2018, closing a stake of 494,361 shares — an estimated $113M sold.

ClearBridge LLC (Maryland) first reported a position in AKBA in Q2 2018 and held it in 1 quarter. The position peaked at $113M in Q2 2018. 130 funds tracked by Wall St. Rank hold AKBA as of Q3 2018.

  • ClearBridge LLC (Maryland) reported no remaining Akebia Therapeutics position as of Q3 2018 after selling out during the quarter.
  • ClearBridge LLC (Maryland) sold 494,361 Akebia Therapeutics shares in Q3 2018, an estimated $113M.
  • ClearBridge LLC (Maryland) first reported a position in Akebia Therapeutics in Q2 2018 and held it in 1 quarter.
  • ClearBridge LLC (Maryland)'s Akebia Therapeutics position peaked at $113M in Q2 2018.
  • 130 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2018.

Based on ClearBridge LLC (Maryland)'s 13F filing for Q3 2018, filed 14 Nov 2018.